BioCryst licenses flu jab to CSL subsidiary; Sucampo says China FDA accepts AMITIZA clinical IND;

> Sucampo Pharmaceuticals said the China FDA has accepted an IND application for a pivotal study of AMITIZA in patients with chronic idiopathic constipation with Harbin Gloria Pharmaceuticals to design and conduct the study under the terms of its exclusive license agreement in China. Release

> Japan's Astellas Pharma Europe said preliminary data from a Phase I/II trial on safety, tolerability and efficacy of ASP2215 for relapsed or refractory acute myeloid leukemia were presented at the 20th Congress of the European Hematology Association in Vienna with a Phase III effort planned to start in late 2015. Release

> Jiangsu Kanion Pharma said one of its products is included in China's MERS treatment procedure guidelines. Release (PDF) (Chinese)

> Lijun International Pharmaceutical says Hebei Hanlin Biotechnology obtained 6 production approvals on serum-free media for stem cells for polypropylene ampules for glucose injections and sterile water. Release (PDF)

> The Indian medical device sector largely supports plans to tighten industry rules, according to RAPS. Report

> Australia's Avita Medical said it has secured a second U.S. patent application for a novel composition of epithelial cell suspension in connection with regenerative products ReCell, ReNovaCell and ReGenerCell. Release (PDF)

> HK-listed Ningbo Lansen has signed a distribution agreement with Bio-Rad China for clinical diagnostic products for at least two years, the company said. Release (PDF)

> China's HyBio suspended share trading pending a news release on June 18 to announce major plan. Release (Chinese)

> BioCryst Pharmaceuticals said it has licensed RAPIVAB (peramivir injection) for the treatment of influenza to Australia's CSL subsidiary, bioCSL, with the drug already licensed in Japan and South Korea. Release

> Japan's Astellas and Medivation ($MDVN) announced the first patient enrollments in TRUMPET, a prospective observational patient registry designed to better understand treatment for patients with castration-resistant prostate cancer. Release